



COMPANY NEWSLETTER

July 2017

MESSAGE FROM THE MANAGING DIRECTOR



It has been an amazing quarter for Proteomics International - we are now the world's most highly accredited protein testing laboratory, the clinical validation study results for PromarkerD were positive, and our new pharmacokinetic (PK) testing services were launched.

These achievements encapsulate our business ethos – quality, innovation, and a growing revenue stream, and

this newsletter provides an outline of each of these areas with further details on our websites – please explore!

I say websites because we now have a dedicated website for PromarkerD, Proteomics International's world leading predictive test for diabetic kidney disease. We also continue to expand and update www.proteomics.com.au with key developments and new services.

Through the quarter we have presented to a number of investor groups across the country to increase awareness of our global successes. To improve our shareholder engagement we are also pleased to welcome on board Canary Capital to provide Investor Relations services.

To support our growth strategy, in May we conducted another successful Trade Visit to India, the world's leading manufacturer of biosimilars. This will be followed by another trip in September as we highlight our analytical services in biosimilars QC and stability testing, PK testing, and companion diagnostics.

Finally, I would like to welcome Shane Herbert to the team as our new Customer Services Manager. Shane brings a wealth of business development experience so please contact him with any of your needs or ideas. Shane's appointment follows the return to Europe of Andreja Livk who served Proteomics International loyally for 16 years. Thanks Andreja, we would not be here without you!

Richard Lipscombe, PhD
Managing Director

IN THIS ISSUE


- Pharmacokinetic testing services launched**
- PromarkerD clinical validation study results**
- PromarkerD new website**
- Staff profile: Customer Services Manager**
- Upcoming event: India Trade Visit**



Proteomics International launches pharmacokinetic and companion diagnostic testing for clinical trials

The company has advanced the analytical services branch of its business in May with the introduction of new pharmacokinetic and companion diagnostic testing targeting pre-clinical and clinical trials.

These services were launched off the back of Proteomics International gaining ISO 17025 Research & Development certification, which includes compliance with the OECD Principles of Good Laboratory Practice (GLP). This extended the company's existing certification for ISO 17025 in the field of Chemical Testing, and makes Proteomics International the world's most accredited protein testing laboratory.



Pharmacokinetics is the study of how the body affects a drug, whereas pharmacodynamics and companion diagnostics profile patient response to treatment by measuring markers in the blood. Together they monitor response to a new drug and in the future may help doctors develop personalised treatments.

Proteomics International's services include:

- Method development of quantitative assays for drugs in biological matrices using industry standard LC-MS/MS systems.
- Method development and validation is conducted in accordance with international recognised regulatory standards.
- Sample testing and reporting utilises validated software.

Staff Profile

Mr Shane Herbert: Customer Services Manager

Shane Herbert joined Proteomics International in June 2017 as the Customer Services Manager and undertakes the role of Study Director, managing the company's pharmacokinetics, biosimilars/biologics and biomarker projects. He is also tasked with implementing business development strategies for new expanding areas for the company.

Shane combines a strong customer focus and commercial conduct with the technical nature of technology driven services. Shane is experienced in technical training and applications support, project management, forecasting, budgeting and international communication.

Shane has significant commercial Life Sciences experience gained from working with various companies including private biotech, large pharma, commercial instrument vendors and most recently with the Australian Genome Research Facility.



Proteomics International India Trade Visit

September 4-8 ■ Hyderabad ■ Chennai ■ Bangalore

Biosimilars, Biologics and Biomarker Discovery

Special Networking Evening in Hyderabad

Tuesday, 5th September Venue to be announced

Please visit our [website](#) for more info



Clinical validation study confirms PromarkerD effectiveness, results presented to world's largest gathering of diabetes experts

Proteomics International took a major step towards global commercialisation of PromarkerD with a validation study confirming the test can predict diabetic kidney disease better than any current measure. In its follow-up clinical validation study, PromarkerD predicted 86% of previously disease-free patients who went on to develop chronic kidney disease within four years.

The results were presented at the American Diabetes Association's 77th Annual Scientific Sessions in June, the world's largest and most prominent meeting of diabetes experts. The four-year study was conducted in collaboration with The University of Western Australia (Fremantle Diabetes Study), and was the largest prospective clinical study on diabetic kidney disease in the community and evaluated PromarkerD with almost 800 patients.

The study follows a Frost & Sullivan report released in March that identified PromarkerD as the world's leading test for diabetic kidney disease. The test has the potential to save healthcare systems around the world billions in costs associated with treating diabetic kidney disease, as well as deliver substantial revenues to Proteomics International in the form of licensing fees and royalties.

The Fremantle Diabetes Study

The Fremantle Diabetes Study (FDS) is a longitudinal observational study of a community-based, urban population in Fremantle, Western Australia. The study, which commenced in 1993 with a more recent phase II in 2008, contains over 3,000 recruits. The strengths of the FDS are the inclusive and representative nature of the cohorts, the range and detail of data collection and linkage to well-established morbidity and mortality databases.

PromarkerD meeting the needs for true personalised medicine

A new approach to managing diabetic kidney disease

- Early detection, intervention and monitoring
- Targeted treatments and medications
- Disease progression management
- As an endpoint marker in clinical trials for any new drug
- PromarkerD may be useful risk stratification in future clinical trials



PromarkerD
CHANGING LIVES

New website launched
www.PromarkerD.com

PROTEOMICS – FAST FACT PANEL

COMPANY CONTACTS

Dr Richard Lipscombe
Managing Director

Mr Chuck Morrison
Head of Business Development

Mr Shane Herbert
Customers Services Manager

Dr Pearl Tan
Chief Operating Officer

Dr Scott Bringans
Research Manager

Mr Paul Hart (Canary Capital)
Investor Relations

AGENTS

India
Proteomics International – India
www.proteomicsindia.com
info-india@proteomics.com.au
P: + 91 8527 699 192

Malaysia/ Indonesia/ Thailand
First BASE Laboratories S/B
www.base-asia.com
peptide-my@base-asia.com
P: + 603 8943 3252

Singapore
Axil Scientific Pte Ltd
www.axilscientific.com
peptide@axilscientific.com
P: + 65 6775 7318

Japan
Leave a Nest Co. Ltd
www.leaveanest.com
info@leaveanest.com
P: + 81 3 6277 8041

Hong Kong/ China
Asia Bio Channel Limited
www.asiabiochannel.com
bcoissac@asiabiochannel.com
P: + 852 9845 4791

Latin America
LinkPharma LLC
www.linkpharma.co
customerservice@linkpharmaus.com
P: +1 813 319 3972

Listing
Australian Securities Exchange

Stock Code
ASX: PIQ

Canary Capital
www.canarycapital.com.au
phart@canarycapital.com.au
P: +61 3 9890 6846
M: +61 421 051 474

Cash Position
A\$1.2 million (30/06/2017)

Issued Capital – Ordinary shares
59.0 million

Market Capitalisation based on share price of 18 cents
A\$10.6 million

Proteomics International is a wholly owned subsidiary of Proteomics International Laboratories Limited (ASX: PIQ)

FOR FURTHER INFORMATION PLEASE CONTACT:

Proteomics International Laboratories Limited

 +61 8 9389 1992

 info@proteomics.com.au (general)
bd@proteomics.com.au (business development)

 www.proteomics.com.au
www.proteomicsinternational.com

 QEII Medical Centre
6 Verdun Street, Nedlands
Perth WA 6009 Australia

Forward looking statement

Any forward looking statements in this newsletter have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors many of which are outside Proteomics International Laboratories Limited's control. Important factors that could cause actual results to differ materially from any assumptions or expectations expressed or implied in this newsletter include known and unknown risks. As actual results may differ materially to any assumptions made in this newsletter, you are urged to view any forward looking statements contained in this newsletter with caution. This newsletter should not be relied on as a recommendation or forecast by Proteomics International Laboratories Limited, and should not be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.